The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 33, No. 7, pp. 812-815. DOI 10.1345/aph.18273
© 1999 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shepherd, G
Right arrow Articles by Edwards, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shepherd, G
Right arrow Articles by Edwards, R


Research Articles

Donepezil overdose: a tenfold dosing error

G Shepherd, W Klein-Schwartz, and R Edwards

OBJECTIVE: To report toxicity resulting from donepezil administration following a tenfold dosing error. CASE SUMMARY: A 79-year-old white nursing home patient with a history of Alzheimer disease and hypertension was inadvertently given 50 mg of donepezil instead of her usual 5-mg dose. She presented to the emergency department with nausea, vomiting, and persistent bradycardia (HR in the 40s). Routine laboratory studies were all within normal limits. Basilar rales were noted five hours after arrival. She was treated with atropine 0.2 mg as needed for bradycardia (HR <50 beats/min); a total of 3.0 mg was administered over 18 hours. Each bolus kept her HR >60 beats/min for one-half to two hours. No further vomiting or evidence of pulmonary edema occurred after her initial episodes. She returned to baseline by day 2 (HR in the 70s) and was returned to the nursing home. DISCUSSION: Donepezil is a centrally acting, reversible cholinesterase inhibitor that is used in the treatment of Alzheimer disease. Donepezil is highly specific for neural acetylcholinesterases, preferentially binding acetylcholinesterase by greater than three orders of magnitude over butyrylcholinesterases. This specificity minimizes peripheral adverse effects at therapeutic doses. Our patient mainly experienced bradycardia and had minimal secretory effects compared with what is usually seen with nonspecific cholinesterase inhibition. Medication errors like the one that produced this overdose are a common but preventable cause of morbidity in healthcare facilities. CONCLUSIONS: A tenfold dosing error caused donepezil toxicity. The main effect of this overdose was bradycardia, which responded to atropine therapy.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
K. R McCain, T. S Sawyer, and H. A Spiller
Evaluation of Centrally Acting Cholinesterase Inhibitor Exposures in Adults
Ann. Pharmacother., October 1, 2007; 41(10): 1632 - 1637.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. Bordier, M. Colsy, F. Robert, and G. Bourenane
Prevalence of positive carotid sinus massage and related risk of syncope in patients with Alzheimer's disease
Europace, September 1, 2007; 9(9): 829 - 834.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
J. P. Rowland, J. Rigby, A. C. Harper, and R. Rowland
Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol
Advan. Psychiatr. Treat., May 1, 2007; 13(3): 178 - 184.
[Abstract] [Full Text] [PDF]


Home page
Emerg. Med. J.Home page
T Suleyman, P Tevfik, G Abdulkadir, and S Ozlem
Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.
Emerg. Med. J., August 1, 2006; 23(8): 641 - 642.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. Bordier, S. Garrigue, S. S. Barold, N. Bressolles, S. Lanusse, and J. Clémenty
Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors
Europace, January 1, 2003; 5(4): 429 - 431.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1999 by Harvey Whitney Books Company.